Table 1

PCR primer sequences used in this study"

Fig. 1

Construction and detection of recombinant viruses A. Schematic diagram of fluorescent tagged virus construction; B. Recombinant virus infection in different generations (P1, P3, P5, P7) (magnification 20×); C. Fluorescence intensity of fluorescent tagged viruses after infection of different generations; D. PCR identification of fluorescently labeled strains from the seventh round of virus plaque purification (M. DL2000 marker; lanes 1-7. Amplification products using the DNA of the fluorescently labeled viruses as templates; lane 8. Amplification products using the DNA of the parent PRV strains as templates)"

Fig. 2

Proliferation properties of recombinant viruses A-B. Determination of phlebotomine size of different virulent strains. The fluorescent gene insertion had an effect on the formation of viral phage size, with significant differences between Ea and Ea-mCherry at P < 0.01 (**), and hSD-1/2019 and hSD-mCherry at P < 0.001 (***); C-D. One-step growth curve determination of viruses showed that the difference in viral titres between recombinant viruses and parental viruses was significant at P < 0.001 (***); E-F. Virus titer (E) and fluorescence intensity (F) of fluorescent strains of different generations"

Fig. 3

Anti-PRV drug screening using fluorescent labeled PRV-mCherry A. Fluorescence intensity inhibition of PRV-mCherry by 1 624 drugs from the Natural Products Library; B-D. Viral fluorescence intensity (B), viral titer (C), and viral copy number (D) were measured after 36 h of co-culture with a 0.01 MOI dose of PRV infection and treatment with candidate drugs, respectively"

Fig. 4

CC50 and IC50 determination of drug candidates A. CC50 assay of 5 drug candidates on PK-15 cells; B. IC50 determination of 5 drug candidates on PK-15 cells"

Table 2

CC50, IC50 and SI of drug candidates"